Hearts and Minds Investments Limited


A group of Australian fund managers have joined forces to launch a listed investment company - called Hearts and Minds Investments Limited - that will not only provide investors with a high conviction portfolio, but will also support leading Medical Research Institutes in Australia.

Hearts and Minds Investments Limited will invest in a concentrated portfolio of approximately 25 securities based on the highest conviction ideas from two groups of fund managers listed below.

Core fund managers - 60% of the LIC’s portfolio will be held in approximately 15 stocks based on three recommendations, reviewed quarterly, from each of five leading fund managers: Caledonia, Cooper Investors, Magellan, Paradice Investment Management and Regal Funds Management.

Conference fund managers - 40% of the LIC’s portfolio will be held in approximately 10 stocks based on the recommendations of fund managers presenting at the annual Sohn Hearts and Minds Investment Conference.

The LIC will donate 1.5% (plus GST) per annum of the average net tangible assets (NTA) for the previous half year to designated charities every 6 months.

The LIC has already received pre-commitments exceeding $225 million and is seeking to raise $500 million. It will not accept over subscriptions and a listing date of 21 November 2018 is proposed.

Hearts & Minds Investments Hearts and Minds Investments Limited Launched on 15 October 2018 Designed for retail investors. Find out more Industry Moves does not hold an AFS Licence and neither recommends nor endorses this product/service.

"I am passionate about supporting medical research": Q&A with Regal Funds Management's Philip King


Industry Moves speaks to Philip King, CIO of Regal Funds Management, and a core fund manager of the new Hearts and Minds listed investment company, about the high conviction LIC, which aims to provide support to medical research. He explains why medical research funding is not only critical for finding cures and medicines that prevent and treat diseases, but it can also reap a significant return on investment in health benefits.